155 related articles for article (PubMed ID: 32210617)
1. Impact of the Activation Status of the Akt/mTOR Signalling Pathway on the Clinical Behaviour of Synovial Sarcoma: Retrospective Analysis of 174 Patients at a Single Institution.
Li YX; Ding SS; Wen WJ; Han L; Wang HQ; Shi HY
Cancer Manag Res; 2020; 12():1759-1769. PubMed ID: 32210617
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma.
Setsu N; Kohashi K; Fushimi F; Endo M; Yamamoto H; Takahashi Y; Yamada Y; Ishii T; Yokoyama K; Iwamoto Y; Oda Y
Cancer; 2013 Oct; 119(19):3504-13. PubMed ID: 23861137
[TBL] [Abstract][Full Text] [Related]
3. mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior.
Ferrandiz-Pulido C; Masferrer E; Toll A; Hernandez-Losa J; Mojal S; Pujol RM; Ramon y Cajal S; de Torres I; Garcia-Patos V
J Urol; 2013 Dec; 190(6):2288-95. PubMed ID: 23764082
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
5. Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer.
Millican-Slater RA; Sayers CD; Hanby AM; Hughes TA
Br J Cancer; 2016 Jul; 115(3):339-45. PubMed ID: 27280636
[TBL] [Abstract][Full Text] [Related]
6. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma.
Campbell L; Jasani B; Edwards K; Gumbleton M; Griffiths DF
Br J Cancer; 2008 Mar; 98(5):931-40. PubMed ID: 18283322
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.
Korkolopoulou P; Levidou G; El-Habr EA; Piperi C; Adamopoulos C; Samaras V; Boviatsis E; Thymara I; Trigka EA; Sakellariou S; Kavantzas N; Patsouris E; Saetta AA
Histopathology; 2012 Aug; 61(2):293-305. PubMed ID: 22690797
[TBL] [Abstract][Full Text] [Related]
8. Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas.
Ishii T; Kohashi K; Iura K; Maekawa A; Bekki H; Yamada Y; Yamamoto H; Nabeshima K; Kawashima H; Iwamoto Y; Oda Y
Tumour Biol; 2016 Apr; 37(4):4767-76. PubMed ID: 26518767
[TBL] [Abstract][Full Text] [Related]
9. Obesity is associated with higher 4E-BP1 expression in endometrial cancer.
Libby EF; Azrad M; Novak L; Vazquez AI; Wilson TR; Demark-Wahnefried W
Curr Biomark Find; 2014 Jan; 2014(4):1-7. PubMed ID: 24639918
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy.
Benavente S; Vergés R; Hermosilla E; Fumanal V; Casanova N; García A; Ramón Y Cajal S; Giralt J
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1316-22. PubMed ID: 19362787
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases.
Akcakanat A; Sahin A; Shaye AN; Velasco MA; Meric-Bernstam F
Cancer; 2008 Jun; 112(11):2352-8. PubMed ID: 18386830
[TBL] [Abstract][Full Text] [Related]
12. The expression and significance of p4E-BP1/4E-BP1 in prostate cancer.
Wang KY; Wang KJ; Ma Q
J Clin Lab Anal; 2022 Apr; 36(4):e24332. PubMed ID: 35257419
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of phosphorylated mammalian target of rapamycin for disease-free survival in breast cancer patients receiving neoadjuvant chemotherapy.
Wang S; Sun Y; He A; Zheng C; Zheng X
Oncol Lett; 2014 Dec; 8(6):2642-2648. PubMed ID: 25364442
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
15. Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.
Okumura Y; Kohashi K; Tanaka Y; Kato M; Maehara Y; Ogawa Y; Oda Y
Virchows Arch; 2020 Jun; 476(6):881-890. PubMed ID: 31927624
[TBL] [Abstract][Full Text] [Related]
16. Expression profiles of mTOR pathway proteins in porocarcinoma: A provisional immunohistochemical study.
Ishida M; Okabe H
Biomed Rep; 2013 Jan; 1(1):28-30. PubMed ID: 24648888
[TBL] [Abstract][Full Text] [Related]
17. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
18. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
19. Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma.
Campbell L; Jasani B; Griffiths DF; Gumbleton M
Am J Cancer Res; 2015; 5(9):2838-48. PubMed ID: 26609489
[TBL] [Abstract][Full Text] [Related]
20. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas.
Setsu N; Yamamoto H; Kohashi K; Endo M; Matsuda S; Yokoyama R; Nishiyama K; Iwamoto Y; Dobashi Y; Oda Y
Cancer; 2012 Mar; 118(6):1637-48. PubMed ID: 21837670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
